Back to Search
Start Over
Aripiprazole in treatment of Gilles de la Tourette syndrome – New therapeutic option
- Source :
- Neurologia i Neurochirurgia Polska. 52:84-87
- Publication Year :
- 2018
- Publisher :
- VM Media SP. zo.o VM Group SK, 2018.
-
Abstract
- Aripiprazole is a dopamine D2- and serotonin 5-hydroxytryptamine (5-HT)1A receptor partial agonist and 5-HT2A receptor antagonist primarily used for the treatment of schizophrenia, bipolar disorder or depression with psychotic ideation. However, recently a number of new possible indications have been suggested, among them Gilles de la Tourette syndrome (GTS). In two randomized, double-blind, placebo-controlled studies in children and adolescents with GTS has been confirmed the efficacy of aripiprazole in tic reduction. In comparison to other neuroleptics, aripiprazole seems to be similarly effective. What is more, the number and profile of possible adverse effects is also favorable. As a consequence, aripiprazole had been registered by Food and Drug Administration (FDA) for the treatment of tics and represents new therapeutic option in treatment of GTS.
- Subjects :
- Oncology
medicine.medical_specialty
Tics
Aripiprazole
Partial agonist
Tourette syndrome
03 medical and health sciences
0302 clinical medicine
Double-Blind Method
Dopamine receptor D2
Internal medicine
medicine
Humans
Bipolar disorder
Psychiatry
Adverse effect
business.industry
medicine.disease
030227 psychiatry
Schizophrenia
Tic Disorders
Surgery
Neurology (clinical)
business
030217 neurology & neurosurgery
Tourette Syndrome
medicine.drug
Subjects
Details
- ISSN :
- 00283843
- Volume :
- 52
- Database :
- OpenAIRE
- Journal :
- Neurologia i Neurochirurgia Polska
- Accession number :
- edsair.doi.dedup.....f4183c9e15fdfbc6228e19c08faefeae